{"id":"W4396668167","doi":"10.1016/j.ymthe.2024.04.036","title":"Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"ca_institutions":"Biotechnology Research Institute","funders":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine; National Natural Science Foundation of China; National Medical Research Council; Chinese Academy of Meteorological Sciences; Chinese Academy of Sciences; Institute of Biophysics, Chinese Academy of Sciences","keywords":"Immune system; Antigen; Immunity; Vaccination; Immunology; CD8; Cancer research; Medicine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":{"n_in":0,"stratum":"aff_core","weight":5595.2375,"opus":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Development of an mRNA therapeutic vaccine for HPV-related malignancies; the object is a vaccine."},"gpt":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"It concerns development of a therapeutic cancer vaccine, not research practice."},"grok":{"tier":"OUT","genre":"other","about_ca":false,"confidence":"high","reason":"Therapeutic HPV mRNA vaccine development; biomedical product research, not metaresearch."}},"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002143181,0.0002737305,0.0002902721,0.0001878655,0.0001713933,0.000396248,0.0002364911,0.0003720862,0.001905015],"category_scores_gemma":[0.0001767494,0.0001237788,0.0002745444,0.000115901,0.000198553,0.0002099065,0.0002387392,0.0008736498,0.0005947307],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003391737,"about_ca_system_score_gemma":0.0004192045,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004868532,"about_ca_topic_score_gemma":0.0004929458,"domain_scores_codex":[0.9998653,0.00001790455,0.000006720748,0.00002362919,0.00004436989,0.0000421198],"domain_scores_gemma":[0.9999497,0.00001045419,0.000008233103,0.000006228134,0.00001303319,0.00001234457],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001350904,0.0001461396,0.0002898257,0.00005727622,0.000009145268,0.00005390347,0.00001673662,0.0007014318,0.9871552,0.0003836695,0.0002194186,0.01083213],"study_design_scores_gemma":[0.0001256323,0.00258248,0.001899989,0.00001764702,0.00005289466,0.0003462942,0.00004983278,0.004593515,0.9750944,0.0001703856,0.01505593,0.00001091156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9670119,0.00269742,0.02197384,0.0005799576,0.0003043553,0.0003732939,0.0005755803,0.0002150133,0.006268609],"genre_scores_gemma":[0.9761371,0.001653845,0.01452661,0.000216601,0.00006010216,0.0001890265,0.001506335,0.00003893758,0.005671448],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001905015,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01119208749612065,"score_gpt":0.2479797627416487,"score_spread":0.236787675245528,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}